COMPASS Pathways plc

Fundamentals4.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Liquidity Improved
  • Persistent Losses
  • High Valuation

AI
AI Summary

6.0

CMPS has evolved into an approval-and-commercialization bet: COMP360's durable, infrequent dosing could justify its premium valuation only if Compass proves supervised treatment can be reimbursed and scaled economically; investors should watch FDA timing and payer/provider adoption, as delays or weak clinic economics would extend cash burn and raise dilution risk.

DurabilityUpside
ExecutionRisk
FDA‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • •Liquidity Improved
  • •Persistent Losses
  • •High Valuation

CMPS's liquidity and equity improved materially, but its pre-revenue status, heavy losses, high liabilities, and 22.3x book valuation make it a high-risk, execution-dependent investment.

BalanceSheetRecovery
HighRisk

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • •Constructive uptrend
  • •Resistance test
  • •Elevated volatility

CMPS is in a constructive last-month uptrend above key averages, but must decisively clear $15.17–$15.20 resistance or risk a pullback toward $14.00–$14.20 support.

CMPS
TechnicalOutlook
Support Level: $14.00–$14.20
Resistance Level: $15.17–$15.20

Sharp reversal from $15.17 to $13.80 highlights volatility risk

Sentiment & News

6.0

Key News Insights:

  • •Sustained trial efficacy
  • •Commercial readiness
  • •Competitive pressures

Compass' strong 52-week COMP360 data and commercialization efforts support CMPS momentum, though competitive and regulatory risks remain.

CMPS
PsychedelicTherapy

Positive clinical results may strengthen CMPS sentiment, but execution and approval timing remain key catalysts